XORTX Therapeutics Inc.
Symbol: TSXV: XRTX NQ: XRTX
Market Cap: 21MPurpose Raise Awareness, Open Market Buying
- XORTX is a biopharmaceutical company pioneering new innovative therapies for progressive kidney disease by leading the development of first-in-class Uric Acid Lowering Agents – innovative therapies to improve the quality of life of patients by slowing progression of kidney disease
- XORTX’s XRx-008, for autosomal dominant polycystic kidney disease (ADPKD) is advancing on the path to FDA market approval
- XORTX is poised to initiate late stage clinical trials for 2 drug-based therapies – XRx-008 for ADPKD and XRX-101 to treat acute kidney injury and other health consequences associated with serious viral infections such as have been described for Coronavirus / COVID-19